文献速递MDS 与骨髓增殖性肿瘤

基因变异对接受JAK1/2抑制剂治疗的骨髓纤维化患者结局的影响

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
PubMed 文献 · Blood Adv · 2017-09-08

该研究对100例接受芦可替尼(n=77)或莫美替尼(n=23)治疗的骨髓纤维化患者进行54基因髓系靶向测序,分析突变谱与治疗结局的关系。ASXL1突变(HR 1.86,P=.03)、EZH2突变(HR 2.94,P=.009)及高分子风险特征(HR 2.06,P=.01)与更短的治疗失败时间相关,多因素分析显示ASXL1或EZH2突变独立关联更短的治疗失败时间和总生存期。

要点

  • ASXL1突变(HR 1.86,P=.03)和EZH2突变(HR 2.94,P=.009)与更短的治疗失败时间相关。
  • 高分子风险特征(HR 2.06,P=.01)与更短的治疗失败时间相关。
  • 多因素分析显示ASXL1或EZH2突变独立关联更短的治疗失败时间和总生存期。

核心结论

  • ASXL1或EZH2突变及高分子风险特征与接受JAK1/2抑制剂治疗的骨髓纤维化患者更短的治疗失败时间相关,并独立关联更短的总生存期。

研究设计与样本

  • 采用54基因髓系靶向测序 panel 对100例接受芦可替尼(n=77)或莫美替尼(n=23)治疗的骨髓纤维化患者进行测序,并将突变谱与治疗结局进行关联分析。

主要发现

  • 99例患者至少检出1个突变,46例(46%)有2个突变,34例(34%)有≥3个突变。
  • 79例携带JAK2V617F突变,14例有CALR突变,6例有MPL突变,2例为三阴性。
  • 无任何突变与脾脏缓解或贫血缓解显著相关。
  • 高动态国际预后评分系统评分和治疗前输血依赖与更短的治疗失败时间相关,多因素分析中该关联保持显著。
  • ASXL1突变(HR 1.86,P=.03)、EZH2突变(HR 2.94,P=.009)及高分子风险特征(HR 2.06,P=.01)与更短的治疗失败时间相关;多因素分析显示ASXL1或EZH2突变独立关联更短的治疗失败时间和总生存期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In myelofibrosis (MF), driver mutations in JAK2, MPL, or CALR impact survival and progression to blast phase, with the greatest risk conferred by triple-negative status. Subclonal mutations, including mutations in high-molecular risk (HMR) genes, such as ASXL1, EZH2, IDH1/2, and SRSF2 have also been associated with inferior prognosis. However, data evaluating the impact of next-generation sequencing in MF patients treated with JAK1/2 inhibitors are lacking. Using a 54-gene myeloid panel, we performed targeted sequencing on 100 MF patients treated with ruxolitinib (n = 77) or momelotinib (n = 23) and correlated mutational profiles with treatment outcomes. Ninety-nine patients had at least 1 mutation identified, 46 (46%) had 2 mutations, and 34 (34%) patients had ≥3 mutations. Seventy-nine patients carried a mutation in JAK2V617F, 14 patients had mutations in CALR, 6 patients had an MPL mutation, and 2 patients were triple negative. No mutation was significantly associated with spleen or anemia response. A high Dynamic International Prognostic Scoring System score and pretreatment transfusion dependence were associated with a shorter time to treatment failure (TTF), and this association retained significance on multivariable analysis. Patients with ASXL1 (hazard ratio [HR], 1.86; P = .03) and EZH2 mutations (HR, 2.94; P = .009) and an HMR profile (HR, 2.06; P = .01) had shorter TTF. On multivariate analysis, ASXL1 or EZH2 mutations were independently associated with shorter TTF and overall survival. These findings help identify patients unlikely to have a durable response with current JAK1/2 inhibitors and provide a framework for future studies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Spiegel JY, McNamara C, Kennedy JA, et al. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood Adv. 2017. PMID: 29296819. doi:10.1182/bloodadvances.2017009530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。